Analysts’ Top Healthcare Picks: EPZM, SIEN

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (NASDAQ: EPZM) and Sientra (NASDAQ: SIEN) with bullish sentiments.

Epizyme (NASDAQ: EPZM)

In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $24. The company’s shares closed yesterday at $19.05.

According to TipRanks.com, Porges is a 4-star analyst with an average return of 8.4% and a 49.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.29, representing a 27.5% upside.

In a report released today, SunTrust Robinson also maintained a Buy rating on the stock with a $27 price target.
Sientra (NASDAQ: SIEN)

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Sientra (NASDAQ: SIEN) today and set a price target of $18. The company’s shares closed yesterday at $10.03.

According to TipRanks.com, Rose is a 4-star analyst with an average return of 10.2% and a 53.8% success rate. Rose covers the Healthcare sector, focusing on stocks such as ReShape Lifesciences Inc, Obalon Therapeutics Inc, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Sientra is Strong Buy and the average price target is $16, representing a 59.5% upside.

In a report issued on February 28, William Blair also reiterated a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.